The transaction is valued at an enterprise value of $250 million (₹21,850 crore) on a cash-free, debt-free basis, including normalised working capital levels.
Founded in 1942 and headquartered in Trevose, Pennsylvania, USA, Lannett is a US-based manufacturer and supplier of complex generic pharmaceuticals, including DEA-controlled substances.
Also Read: Aurobindo Pharma shares decline nearly 4% after Andhra unit operations stalled for 20-25 days
The company specialises in non-opioid controlled substances, particularly ADHD treatments, and has launched multiple generic liquids in the market. Lannett operates a 425,000 square feet cGMP manufacturing facility in Seymour, Indiana, with an annual capacity of approximately 3.6 billion tablets and a strong regulatory compliance record.
This acquisition is aligned with Aurobindo’s strategy to expand its U.S. manufacturing footprint and enhance its presence in the domestic market. The deal gives Aurobindo access to a complementary product portfolio, a growing CDMO (Contract Development and Manufacturing Organisation) business, and significant excess capacity for future expansion.
Aurobindo currently has limited exposure in the ADHD therapeutics space, and this acquisition offers strategic diversification into a high-value segment. The transaction is subject to regulatory approvals, including clearance from the US Federal Trade Commission, and is expected to be completed within 8 to 12 months. The acquisition will be funded through cash consideration.
Also Read: Aurobindo Pharma shares get an upgrade after a 25% drop from peak on attractive valuations
Shares of Aurobindo Pharma Ltd ended at ₹1,153.50, down by ₹4.60, or 0.40%, on the BSE.
